Prospective Multicenter Study Evaluating Feasibility and Efficacy of Tumor Organoid-based Precision Medicine in Patients With Advanced Refractory Cancers

Recruiting now · Not applicable

Conditions studied: Advanced, Pretreated Solid Tumors

In brief

* PDOs are tridimensional multicellular structures expanded in vitro which retain the genotypic and phenotypic features of their tissue or tumor of origin. PDOs can be exposed to a panel of drugs (chemotherapy, hormonal therapy, targeted therapy) in order to study their sensitivity to each agent (or combination of agents) tested ('chemogram'). Recent studies showed that PDOs can accurately predict the response to treatment of solid tumors and could therefore inform clinical decision on the best therapeutic option for each patient. * ORGANOTREAT is a multicenter prospective study program of organoid-based precision oncology encompassing 3 studies: ORGANOTREAT-01, a pilot study restricted to advanced CRC, and ORGANOTREAT-02A and -2B, two Phase 2 studies in advanced solid cancers.

Key facts

Study ID

NCT05267912

Run by

Gustave Roussy, Cancer Campus, Grand Paris

People needed

152

Starts

2022-01-19

Expected to finish

2029-01-18

Last updated by the study team

2026-06-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years
• ECOG performance status 0-1
• Life expectancy >3 months
• Histologically-confirmed, unresectable, locally advanced or metastatic solid tumor
• ORGANOTREAT-01: CRC
• ORGANOTREAT-02A: Colorectal adenocarcinoma (CRC) or pancreatic ductal adenocarcinoma (PDAC)
• ORGANOTREAT-02B: solid cancers with a PDO take-on rate ≥50%:
• Stratum 1: PDAC
• Stratum 2: CRC
• Other strata: to be added by protocol amendment
• ≥1 measurable lesion according to RECIST v1.1
• ≥1 tumor site accessible to biopsy without significant risk, outside from lung lesion
• Patients are to be biopsied before the start or within the 3 first weeks of the SoC line.
• Failure (disease progression or intolerance) or contraindication to validated treatments in the advanced setting; patients MUST be still eligible for at least 1 (ORGANOTREAT-01 and -2A) or 2 (ORGANOTREAT-02B) validated systemic treatment lines according to approved guidelines:
• CRC (ORGANOTREAT-01): failure (disease progression or intolerance) or contraindication to fluoropyrimidines, oxaliplatin, irinotecan, anti-EGFR (in RAS wild-type tumors), anti-BRAF (in BRAF V600E mutated tumors), and antiangiogenics; patients must be still eligible for trifluridine-tipiracil and/or regorafenib
• CRC (ORGANOTREAT-2A): failure (disease progression or intolerance) or contraindication to fluoropyrimidines, oxaliplatin, irinotecan, anti-EGFR (in RAS wild-type tumors), anti-BRAF (in BRAF V600E mutated tumors), and trifluridine-tipiracil/bevacizumab; patients must be still eligible for regorafenib
• PDAC (ORGANOTREAT-2A): Patients will be included at the beginning of their second line of standard therapy
• PDAC (ORGANOTREAT-02B stratum 1): patients will be included at the beginning of their first- or second-line of therapy
• Specifications for supplementary tumor strata in ORGANOTREAT-02 will be defined by protocol amendment
• Adequate hepatic, renal and hematological functions (AST/ALT < 2.5 ULN (5 ULN in cases of liver metastases); Total bilirubin < 1.5 ULN; Albumin > 30 g/L; International normalized ratio (INR) <1.5 ULN; Calculated creatinine clearance >50 mL/min; Absolute neutrophil count >1000/mm3, platelets >100 000/mm3, hemoglobin >9 g/dL) To be performed until 7 days before enrollment
• Informed consent signed by the patient or his/her legal representative
• Affiliation to or beneficiary of a social security system
• A female participant is eligible to participate if she is not pregnant not breastfeeding, and
• Not a woman of childbearing potential (WOCBP) OR
• A WOCBP should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

You may not qualify if…

• History of other invasive cancer within 5 years prior to entry into the trial other than adequately treated basal-cell skin cancer or in situ carcinoma of the cervix
• Concomitant medications/comorbidities that may prevent the patient from being biopsied
• Patients with brain or meningeal metastasis, unless definitive therapy occurred more than 6 months ago and with a confirmation of tumoral control and absence of symptoms within 4 weeks of starting study treatment
• Pregnancy or breast-feeding
• Privation of liberty or guardianship
• Geographical, social or psychological reasons precluding study participation and monitoring
• Coagulation abnormality prohibiting a biopsy

Where it is running

• Gustave Roussy — Villejuif, France (enrolling)
• Centre Oscar Lambret — Lille, France, France (enrolling)
• HIA Bégin — Saint-Mandé, France, France (enrolling)
• Institut Bergonié — Bordeaux, France, France (enrolling)
• Hôpital Saint Louis — Paris, France, France (enrolling)
• Hôpital Pitié-Salpêtrière — Paris, France, France (enrolling)
• Hôpital St Antoine — Paris, France, France (enrolling)
• Institut Godinot — Reims, France, France (enrolling)
• Centre Eugène Marquis — Rennes, France, France (enrolling)
• Centre Léon Bérard — Lyon, France, France
• CHU de Poitiers — Poitiers, France, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.